Entrada Therapeutics/$TRDA
1D1W1MYTD1Y5YMAX
Capital at risk
About Entrada Therapeutics
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
- Ticker
- $TRDA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 152
- Headquarters
- Boston, United States
- Website
- www.entradatx.com
TRDA Metrics
BasicAdvanced
$231M
-
-$3.97
-0.26
-
Price and volume
Market cap
$231M
Beta
-0.26
52-week high
$16.45
52-week low
$5.02
Average daily volume
327K
Financial strength
Current ratio
10.889
Quick ratio
10.515
Long term debt to equity
18.892
Total debt to equity
20.798
Profitability
EBITDA (TTM)
-170.863
Gross margin (TTM)
-2,867.16%
Net profit margin (TTM)
-3,537.73%
Operating margin (TTM)
-3,726.53%
Effective tax rate (TTM)
-0.50%
Revenue per employee (TTM)
$30,000
Management effectiveness
Return on assets (TTM)
-29.20%
Return on equity (TTM)
-54.09%
Valuation
Price to revenue (TTM)
57.245
Price to book
0.99
Price to tangible book (TTM)
0.99
Price to free cash flow (TTM)
-1.997
Free cash flow yield (TTM)
-50.08%
Free cash flow per share (TTM)
-3.215
Growth
Revenue change (TTM)
-94.10%
Earnings per share change (TTM)
121.71%
3-year revenue growth (CAGR)
-52.39%
3-year earnings per share growth (CAGR)
15.57%
What the Analysts think about TRDA
Analyst ratings (Buy, Hold, Sell) for Entrada Therapeutics stock.
Analyst projections of the future price of Entrada Therapeutics stock.
TRDA Financial Performance
Revenues and expenses
TRDA Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing TRDA
AllUSDGBPEUR
Fund name | Fund size | $TRDA weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.02% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.02% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.